Hong Kong Stock Market Update: IMPACT THERAP-B (07630) Surges Nearly 13% on Core Drug Growth and Index Inclusion Prospects

Stock News09-03 15:18

Shares of IMPACT THERAP-B (07630) jumped nearly 13% in Hong Kong trading, last up 11.14% at HK$14.87 with turnover reaching HK$5.15 million.

In a morning announcement, the company disclosed that its executive director and CEO, Cai Suixiong, recently purchased a total of 100,000 ordinary shares on the open market at an average price of approximately HK$14.6105 each, representing about 0.035% of the company's total issued shares. Dr. Cai expressed strong confidence in the group's overall development prospects and potential growth.

Adding to the positive momentum, IMPACT THERAP-B has been included as a constituent of the Hang Seng Composite Index, with the change set to take effect after market close on September 4 and become effective from September 7. The company's shares are expected to meet the criteria for inclusion in the Stock Connect programs covering both Shanghai and Shenzhen.

For the first half of this year, IMPACT THERAP-B reported revenue of RMB 105 million, a year-on-year increase of 316.8%, while its net loss narrowed by 29.5% compared to the same period last year.

Notably, the company's core product, Senaparib, has experienced rapid volume growth since being added to the National Medical Insurance Drug Catalogue on January 1. During the first half, Senaparib's sales revenue in China reached RMB 70.4 million, surging 877.8% year-on-year, with coverage extending to all provinces on the mainland and nearly 1,200 medical institutions.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1102771982?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-03 15:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1102771982","market":"sg","top_or_hot":-1,"title":"Hong Kong Stock Market Update: IMPACT THERAP-B (07630) Surges Nearly 13% on Core Drug Growth and Index Inclusion Prospects","media":"Stock News","content":"<p>Shares of <b>IMPACT THERAP-B</b> (<b>07630</b>) jumped nearly 13% in Hong Kong trading, last up 11.14% at HK$14.87 with turnover reaching HK$5.15 million.<br><br>In a morning announcement, the company disclosed that its executive director and CEO, Cai Suixiong, recently purchased a total of 100,000 ordinary shares on the open market at an average price of approximately HK$14.6105 each, representing about 0.035% of the company's total issued shares. Dr. Cai expressed strong confidence in the group's overall development prospects and potential growth.<br><br>Adding to the positive momentum, <b>IMPACT THERAP-B</b> has been included as a constituent of the Hang Seng Composite Index, with the change set to take effect after market close on September 4 and become effective from September 7. The company's shares are expected to meet the criteria for inclusion in the Stock Connect programs covering both Shanghai and Shenzhen.<br><br>For the first half of this year, <b>IMPACT THERAP-B</b> reported revenue of RMB 105 million, a year-on-year increase of 316.8%, while its net loss narrowed by 29.5% compared to the same period last year.<br><br>Notably, the company's core product, Senaparib, has experienced rapid volume growth since being added to the National Medical Insurance Drug Catalogue on January 1. During the first half, Senaparib's sales revenue in China reached RMB 70.4 million, surging 877.8% year-on-year, with coverage extending to all provinces on the mainland and nearly 1,200 medical institutions.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Market Update: IMPACT THERAP-B (07630) Surges Nearly 13% on Core Drug Growth and Index Inclusion Prospects</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Market Update: IMPACT THERAP-B (07630) Surges Nearly 13% on Core Drug Growth and Index Inclusion Prospects\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-09-03 15:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>IMPACT THERAP-B</b> (<b>07630</b>) jumped nearly 13% in Hong Kong trading, last up 11.14% at HK$14.87 with turnover reaching HK$5.15 million.<br><br>In a morning announcement, the company disclosed that its executive director and CEO, Cai Suixiong, recently purchased a total of 100,000 ordinary shares on the open market at an average price of approximately HK$14.6105 each, representing about 0.035% of the company's total issued shares. Dr. Cai expressed strong confidence in the group's overall development prospects and potential growth.<br><br>Adding to the positive momentum, <b>IMPACT THERAP-B</b> has been included as a constituent of the Hang Seng Composite Index, with the change set to take effect after market close on September 4 and become effective from September 7. The company's shares are expected to meet the criteria for inclusion in the Stock Connect programs covering both Shanghai and Shenzhen.<br><br>For the first half of this year, <b>IMPACT THERAP-B</b> reported revenue of RMB 105 million, a year-on-year increase of 316.8%, while its net loss narrowed by 29.5% compared to the same period last year.<br><br>Notably, the company's core product, Senaparib, has experienced rapid volume growth since being added to the National Medical Insurance Drug Catalogue on January 1. During the first half, Senaparib's sales revenue in China reached RMB 70.4 million, surging 877.8% year-on-year, with coverage extending to all provinces on the mainland and nearly 1,200 medical institutions.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"KCAI","symbol_name":"KraneShares China Alpha Index ETF","start_time":0,"source_url":"","article_id":"1102771982","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1102771982","pubTimestamp":1788419895,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Shares of IMPACT THERAP-B (07630) jumped nearly 13% in Hong Kong trading, last up 11.14% at HK$14.87 with turnover reaching HK$5.15 million.In a morning announcement, the company disclosed that its...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"KCAI":"KraneShares China Alpha Index ETF","BK4588":"碎股","BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","07630":"英派药业-B"},"translate_title":"香港股市最新动态：IMPACT THERAP-B (07630) 因核心药物增长和指数纳入前景飙升近 13%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KCAI":1,"07630":1,"VXUS":1},"content_text":"Shares of IMPACT THERAP-B (07630) jumped nearly 13% in Hong Kong trading, last up 11.14% at HK$14.87 with turnover reaching HK$5.15 million.In a morning announcement, the company disclosed that its executive director and CEO, Cai Suixiong, recently purchased a total of 100,000 ordinary shares on the open market at an average price of approximately HK$14.6105 each, representing about 0.035% of the company's total issued shares. Dr. Cai expressed strong confidence in the group's overall development prospects and potential growth.Adding to the positive momentum, IMPACT THERAP-B has been included as a constituent of the Hang Seng Composite Index, with the change set to take effect after market close on September 4 and become effective from September 7. The company's shares are expected to meet the criteria for inclusion in the Stock Connect programs covering both Shanghai and Shenzhen.For the first half of this year, IMPACT THERAP-B reported revenue of RMB 105 million, a year-on-year increase of 316.8%, while its net loss narrowed by 29.5% compared to the same period last year.Notably, the company's core product, Senaparib, has experienced rapid volume growth since being added to the National Medical Insurance Drug Catalogue on January 1. During the first half, Senaparib's sales revenue in China reached RMB 70.4 million, surging 877.8% year-on-year, with coverage extending to all provinces on the mainland and nearly 1,200 medical institutions.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1102771982","isCrawlerRequest":true}